Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report)'s stock price traded up 14.7% during mid-day trading on Wednesday . The stock traded as high as $8.49 and last traded at $9.17. 46,019 shares traded hands during mid-day trading, a decline of 14% from the average session volume of 53,619 shares. The stock had previously closed at $7.99.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a "neutral" rating and set a $20.00 target price on shares of Lyell Immunopharma in a research note on Wednesday, April 16th.
Get Our Latest Analysis on Lyell Immunopharma
Lyell Immunopharma Stock Down 14.9%
The company has a 50 day moving average of $8.80 and a two-hundred day moving average of $11.97. The firm has a market cap of $169.70 million, a P/E ratio of -14.51 and a beta of -0.26.
Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($3.60) earnings per share for the quarter, beating the consensus estimate of ($3.80) by $0.20. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The business had revenue of $0.01 million during the quarter. Research analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.
Insider Activity
In related news, Director Richard Klausner bought 7,900 shares of Lyell Immunopharma stock in a transaction dated Friday, March 14th. The stock was acquired at an average cost of $12.00 per share, with a total value of $94,800.00. Following the completion of the acquisition, the director now directly owns 42,168 shares in the company, valued at approximately $506,016. This trade represents a 23.05% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Lynn Seely acquired 8,750 shares of Lyell Immunopharma stock in a transaction that occurred on Friday, March 14th. The stock was acquired at an average cost of $12.20 per share, with a total value of $106,750.00. Following the completion of the purchase, the chief executive officer now owns 35,625 shares in the company, valued at approximately $434,625. This represents a 32.56% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 38,432 shares of company stock valued at $449,508 over the last three months. Insiders own 25.10% of the company's stock.
Institutional Investors Weigh In On Lyell Immunopharma
Hedge funds have recently bought and sold shares of the business. Graham Capital Management L.P. purchased a new stake in Lyell Immunopharma in the 4th quarter worth about $33,000. RPO LLC acquired a new stake in shares of Lyell Immunopharma during the 4th quarter valued at about $42,000. Wells Fargo & Company MN lifted its holdings in Lyell Immunopharma by 27.8% in the 4th quarter. Wells Fargo & Company MN now owns 94,320 shares of the company's stock worth $60,000 after purchasing an additional 20,542 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in Lyell Immunopharma during the fourth quarter worth approximately $64,000. Finally, SG Americas Securities LLC grew its holdings in Lyell Immunopharma by 102.8% during the fourth quarter. SG Americas Securities LLC now owns 116,748 shares of the company's stock valued at $75,000 after purchasing an additional 59,182 shares during the last quarter. 66.05% of the stock is owned by hedge funds and other institutional investors.
Lyell Immunopharma Company Profile
(
Get Free Report)
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
Further Reading
Before you consider Lyell Immunopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.
While Lyell Immunopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.